ADCs
Otsuka’s Taiho pays $400M for Swiss partner to ‘turbocharge’ 3 ADCs to clinic
Araris, Taiho, Antibody-Drug Conjugates, Otsuka ‘s, Acquisition (action), ADCs, ADC
Callio Therapeutics Debuts with $187M to Develop Next-Generation Multi-Payload ADCs for Cancer
Multi-payload ADCs, antibody-drug conjugates, oncology, HER2-targeted therapy, dual-payload technology, cancer treatment, biotechnology startup
AstraZeneca and Gilead Explore TROP2 ADCs in Lung Cancer, Seeking Pathways to Approval
TROP2 ADCs, Lung Cancer, AstraZeneca, Gilead, Datopotamab Deruxtecan, Trodelvy, Non-Small Cell Lung Cancer (NSCLC)
OS Therapies Refiles IPO for $6M to Fund Phase 2 HER2 Drug and Preclinical ADCs
OS Therapies, IPO, HER2 drug, preclinical ADCs, immunotherapy, NYSE American exchange
Myricx Secures $114M Funding with Lilly’s Support for ADC Development
Myricx, Eli Lilly, ADCs, Biotech Funding, Series A
ASCO: AbbVie Revamps ADC Portfolio to Replace Chemotherapy
ASCO, AbbVie, ADCs, Chemotherapy, Rova-T, Teliso-V, Cancer Treatment